Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N R Cutler

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
The Journal of Clinical Psychiatry|April 18, 2001
Pharmacokinetic studies of antipsychotics in healthy volunteers versus patientsN R Cutler
Progress in Clinical and Biological Research|January 1, 1989
Methodological concerns: evaluating central nervous system (CNS) active compounds in Alzheimer's disease (AD)N R Cutler
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1986
Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndromeN R Cutler
Neurobiology of Aging|January 1, 1988
Cognitive and brain imaging measures of Alzheimer's diseaseN R Cutler
The American Journal of Psychiatry|October 1, 1977
Explaining benzodiazepines: another approachN R Cutler, D Shore
The American Journal of Psychiatry|July 1, 1978
A question on haloperidol treatment for deliriumN R Cutler, J F Heiser
Journal of Clinical Psychopharmacology|October 1, 1982
State-related cyclical dyskinesias in manic-depressive illnessN R Cutler, R M Post
Drugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R Cutler
The New England Journal of Medicine|March 18, 1993
Tacrine in Alzheimer's diseaseN R Cutler, J J Sramek
The New England Journal of Medicine|January 5, 1995
The use of placebo controlsJ J Sramek, N R Cutler
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
The Journal of Clinical Psychiatry|April 18, 2001
Pharmacokinetic studies of antipsychotics in healthy volunteers versus patientsN R Cutler
Progress in Clinical and Biological Research|January 1, 1989
Methodological concerns: evaluating central nervous system (CNS) active compounds in Alzheimer's disease (AD)N R Cutler
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1986
Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndromeN R Cutler
Neurobiology of Aging|January 1, 1988
Cognitive and brain imaging measures of Alzheimer's diseaseN R Cutler
The American Journal of Psychiatry|October 1, 1977
Explaining benzodiazepines: another approachN R Cutler, D Shore
The American Journal of Psychiatry|July 1, 1978
A question on haloperidol treatment for deliriumN R Cutler, J F Heiser
Journal of Clinical Psychopharmacology|October 1, 1982
State-related cyclical dyskinesias in manic-depressive illnessN R Cutler, R M Post
Drugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R Cutler
The New England Journal of Medicine|March 18, 1993
Tacrine in Alzheimer's diseaseN R Cutler, J J Sramek
The New England Journal of Medicine|January 5, 1995
The use of placebo controlsJ J Sramek, N R Cutler
Pageof 17